BrainsWay partners with clinical practices to deliver patented H-Coil Deep TMS devices for depression, OCD, and smoking addiction.
Public company
1Competitive Advantages
Which advantages over its rivals hold up, and why are they hard to copy?
Among TMS companies, BrainsWay alone holds three FDA-cleared indications, and its patented H-Coils allow treatment to target specific brain areas.
BrainsWay's H1 Coil focuses on the bilateral prefrontal cortex on both sides of the brain.
2Growth Drivers
What could change its growth trajectory, and what would confirm it?
Higher system shipments drive BrainsWay's revenue growth: Q2 2026 revenue rose 35% to $17.1 million on a 42% increase in system shipments in the same quarter.
BrainsWay's installed base reached about 1,949 systems. Updated fiscal 2026 revenue guidance implies 30% to 34% growth, a plan rather than an achieved result.
3Product Overview
What does the product do for its buyer, and how is it delivered?
BrainsWay's Deep TMS platform combines a stimulator with patented H-Coils, while the 104 RCT System supports blinded clinical research. The H1 Coil targets the bilateral prefrontal cortex.
The H7 Coil targets the anterior cingulate cortex, and the H4 Coil targets the bilateral insula. BrainsWay shipped 125 Deep TMS systems in Q2 2026.